IMM01-STEM
Phase 2Biologic
IMM01-STEM is one of 50 biologic programs targeting Obesity. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
177 competitors in Obesity
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Phase 3
Vivia
SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 3
NNC0487-0111
Novo NordiskPhase 3
Mibavademab
RegeneronPhase 3
PF-08653944
PfizerPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Ribupatide
KKailera
Phase 3
Aleniglipron
GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Muscle weakness1 trial
Obesity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMM01-STEM. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmunis, Inc.